NASDAQ:GNOM

Global X Genomics & Biotechnology ETF Stock Forecast, Price & News

$22.08
+0.36 (+1.66 %)
(As of 04/13/2021 10:57 AM ET)
Add
Today's Range
$21.89
Now: $22.08
$22.19
50-Day Range
$21.08
MA: $22.95
$26.37
52-Week Range
$13.15
Now: $22.08
$28.45
Volume1,944 shs
Average Volume179,310 shs
Market Capitalization$203.58 million
P/E RatioN/A
Dividend Yield0.15%
BetaN/A
Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Global X Genomics & Biotechnology ETF logo

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:GNOM
CUSIPN/A
Phone+1-650-9432800
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$203.58 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

4 Best Sector ETFs of Q4
December 24, 2020 |  msn.com
Global X Genomics & Biotechnology ETF
November 26, 2020 |  barrons.com
ETF Wrap: A very ETF Thanksgiving, and tax season too
November 25, 2020 |  finance.yahoo.com
Global X Genomics & Biotechnology ETF (GNOM)
October 18, 2020 |  nasdaq.com
Why You Should Invest in Genomics ETFs
October 15, 2020 |  msn.com
3 Genomics ETFs Worth Jumping For
May 26, 2020 |  www.msn.com
Genomics ETF (GNOM) Hits New 52-Week High
May 26, 2020 |  finance.yahoo.com
Why This Thematic Healthcare Could be a January Winner
January 11, 2020 |  finance.yahoo.com
This High Growth ETF May Not Be As Pricey As You Think
October 10, 2019 |  finance.yahoo.com
ETFs Poised to Benefit from Gene Editing Revolution
September 6, 2019 |  finance.yahoo.com
Inside the Allure of a Genomics ETF
August 3, 2019 |  finance.yahoo.com
A New ETF For Hot Corners of The Biotech Market
June 26, 2019 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$22.08
+0.36 (+1.66 %)
(As of 04/13/2021 10:57 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNOM News and Ratings via Email

Sign-up to receive the latest news and ratings for GNOM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Frequently Asked Questions

What stocks does MarketBeat like better than Global X Genomics & Biotechnology ETF?

Wall Street analysts have given Global X Genomics & Biotechnology ETF a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Global X Genomics & Biotechnology ETF wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF saw a increase in short interest in March. As of March 15th, there was short interest totaling 162,800 shares, an increase of 59.9% from the February 28th total of 101,800 shares. Based on an average daily trading volume, of 174,200 shares, the days-to-cover ratio is presently 0.9 days.
View Global X Genomics & Biotechnology ETF's Short Interest
.

How has Global X Genomics & Biotechnology ETF's stock price been impacted by COVID-19?

Global X Genomics & Biotechnology ETF's stock was trading at $12.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GNOM stock has increased by 70.4% and is now trading at $22.08.
View which stocks have been most impacted by COVID-19
.

How often does Global X Genomics & Biotechnology ETF pay dividends? What is the dividend yield for Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF declared a Semi-Annual dividend on Tuesday, December 29th. Investors of record on Thursday, December 31st will be given a dividend of $0.032 per share on Friday, January 8th. The ex-dividend date is Wednesday, December 30th.
View Global X Genomics & Biotechnology ETF's dividend history
.

Is Global X Genomics & Biotechnology ETF a good dividend stock?

Global X Genomics & Biotechnology ETF pays an annual dividend of $0.03 per share and currently has a dividend yield of 0.15%.
View Global X Genomics & Biotechnology ETF's dividend history.

What other stocks do shareholders of Global X Genomics & Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global X Genomics & Biotechnology ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), (SNY), Intel (INTC), Pfizer (PFE), Quest Diagnostics (DGX), Micron Technology (MU), Dynavax Technologies (DVAX), (MRNA) and Matinas BioPharma (MTNB).

What is Global X Genomics & Biotechnology ETF's stock symbol?

Global X Genomics & Biotechnology ETF trades on the NASDAQ under the ticker symbol "GNOM."

How do I buy shares of Global X Genomics & Biotechnology ETF?

Shares of GNOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global X Genomics & Biotechnology ETF's stock price today?

One share of GNOM stock can currently be purchased for approximately $22.08.

How much money does Global X Genomics & Biotechnology ETF make?

Global X Genomics & Biotechnology ETF has a market capitalization of $203.58 million.

What is Global X Genomics & Biotechnology ETF's official website?

The official website for Global X Genomics & Biotechnology ETF is www.completegenomics.com.

Where are Global X Genomics & Biotechnology ETF's headquarters?

Global X Genomics & Biotechnology ETF is headquartered at 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States.

How can I contact Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF's mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The company can be reached via phone at +1-650-9432800.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.